FDA Approved Medical Products for:

Glycogen storage disease type 2

The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products.

Generic Name Recombinant human acid alpha-glucosidase; alglucosidase alfa
Trade Name
(Manufacturer Name)
Lumizyme
(Genzyme Corporation)
Indication
The FDA has approved this product to be used in this manner.
Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age.
More Information about this product Drug Information Portal

Generic Name Recombinant human acid alpha-glucosidase
Trade Name
(Manufacturer Name)
Myozyme®
(Genzyme Corporation)
Indication
The FDA has approved this product to be used in this manner.
For use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy.
More Information about this product Drug Information Portal